Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ELVN by emailGet an email when ELVN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELVN, unsubscribe in one click. Privacy
📣 What ELVN Says Is Next
second half of 2026 · “Collectively, these data and regulatory milestones continue to support advancement of ELVN-001 into the planned ENABLE-2 Phase 3 trial, which the Company expects to initiate in the second half of 2026.”
Company press release, Aug 5, 2026 · SEC filing
second half of 2026 · “The Company remains on track to achieve its anticipated 2026 milestones, including: o Mid-year presentation of additional Phase 1 data from the ongoing ENABLE trial o Regulatory interactions with the FDA on dose selection and Phase 3 trial design o Initiation of Phase 3 ENABLE-2 in the second half of 2026 First Quarter 2026 Financial Results”
Company press release, May 7, 2026 · SEC filing
in 2026 · “He joins us at a critical time as we plan to initiate a pivotal Phase 3 clinical trial of ELVN-001 in 2026.”
Company press release, Dec 11, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ELVN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELVN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.